| breast cancer HER 2 negative | ||
| es-BC - HER2 negative - (neo)adjuvant (NA) | mBC - HER 2 negative | |
| immune chekpoint inhibitors | ||
| anti-PD-(L)1 | ||
| durvalumab based treatment | ||
| durvalumab alone | Saphir02 Breast-Immuno | |
| pembrolizumab based treatment | ||
| pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | I-SPY2 | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
